Your team already did the work: months of screening, thousands of abstracts, careful inclusion/exclusion decisions. But publication bias hides critical signals in gray literature—clinical trial registries, conference abstracts, failed trials with revealing secondary outcomes.
One missed study isn't just an oversight. It's a competitor's unpublished Phase II data you didn't know existed, or a mechanism-of-action insight buried in a lower-tier journal.
The error rate reality: Manual screening has a 10.76% classification inconsistency rate. That's 1 in 9 abstracts potentially misclassified. When you're building a $15-40M program on the completeness of your mechanistic rationale, verification isn't optional—it's insurance.
Screening verification
Full verification
Everything in screening verification, plus:
Catch missed repurposing signals. Your screening found 47 relevant studies. We found 3 more you missed—including the one with your competitor's failed Phase II data and the conference abstract with secondary endpoint signals.
Publication bias protection. Gray literature contains the studies that didn't make top-tier journals but still matter. Verification ensures your evidence base isn't systematically skewed toward positive findings.
Faster than re-doing, cheaper than missing. Full manual second-reader verification takes weeks. Our verification takes days. And it's orders of magnitude cheaper than building a clinical program on incomplete evidence.
One verification proves the model.

Cofounder & CEO, in previous lives he has worked on Stanford NLP's most popular open-source project, researched multi-agent AI, and studied Systems Design Engineering at the University of Waterloo.